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Serine Protease Signaling of Epidermal Permeability
Barrier Homeostasis
Jean-Pierre Hachem1,2,3, Evi Houben2,3, Debra Crumrine1, Mao-Quiang Man1, Nanna Schurer4,
Truus Roelandt2,3, Eung H. Choi1, Yoshikazu Uchida1, Barbara E. Brown1, Kenneth R. Feingold1
and Peter M. Elias1
Evidence is growing that protease-activated receptor-2 (PAR-2) plays a key role in epithelial inflammation. We
hypothesized here that PAR-2 plays a central role in epidermal permeability barrier homeostasis by mediating
signaling from serine proteases (SP) in the stratum corneum (SC). Since the SC contains tryptic- and
chymotryptic-like activity, we assessed the influence of SP activation/inhibition on barrier function. Acute
barrier disruption increases SP activity and blockade by topical SP inhibitors (SPI) accelerates barrier recovery
after acute abrogation. This improvement in barrier function is due to accelerated lamellar body (LB) secretion.
Since tryptic SP signal certain downstream responses through PAR-2, we assessed its potential role in mediating
the negative effects of SP on permeability barrier. Firstly, PAR-2 is expressed in the outer nucleated layers of the
epidermis and most specifically under basal condition to the lipid raft (LR) domains. Secondly, tape stripping-
induced barrier abrogation provokes PAR-2 activation, as shown by receptor internalization (i.e. receptor
movement from LR to cytolpasmic domains). Thirdly, topical applications of PAR-2 agonist peptide, SLIGRL,
delay permeability barrier recovery and inhibit LB secretion, while, conversely, PAR-2 knockout mice display
accelerated barrier recovery kinetics and enhanced LB secretion, paralleled by increased LR formation and
caveolin-1 expression. These results demonstrate first, the importance of SP/SPI balance for normal
permeability barrier homeostasis, and second, they identify PAR-2 as a novel signaling mechanism of
permeability barrier, that is, of response linked to LB secretion.
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INTRODUCTION
The major function of the epidermis is to generate a protective
barrier between the external environment and the host (Elias,
1983; Madison, 2003). One of these protective functions,
formation of a permeability barrier, limits the transcutaneous
movement of water and electrolytes, a function that is
essential for terrestrial survival (Elias, 1983; Madison, 2003).
This permeability barrier function localizes to the stratum
corneum (SC), the outermost layer of the epidermis. Lipids,
particularly ceramides (Holleran et al., 1991), cholesterol
(Menon et al., 1992b), and free fatty acids (Mao-Qiang et al.,
1993), together form lamellar membranes in the extracellular
spaces of the SC that limit the loss of water and electrolytes
(Harris et al., 1997). Corneocytes are embedded in this lipid-
enriched matrix, and the cornified envelope (Candi et al.,
2005), which surrounds corneocytes, provides a scaffold
necessary for the organization of the lamellar membranes. In
addition, the cornified envelope provides mechanical strength
and rigidity to the skin, thereby protecting the host from injury
(Candi et al., 2005). Adjacent corneocytes are linked by
corneodesmosomes, which are proteolytically degraded,
allowing for the desquamation of corneocytes and in the
surrounding matrix (Caubet et al., 2004). Thus, both
components of the SC, the extracellular lipid-enriched
membranes and the corneocytes, need to be continually
replaced to maintain a structurally intact and functional SC.
When the permeability of the barrier is disrupted by
removal of extracellular lipids by either topical treatment
with solvents, for example, by acetone, or detergents, such as
SDS, or following mechanical injury, for example, by tape
stripping, a homeostatic repair response is initiated in the
underlying epidermis that rapidly corrects the abnormality in
permeability barrier function (Taljebini et al., 1996). An early
step (ie, within 15–30 minutes) in this repair response is the
secretion of lamellar bodies (LB) into the stratum granulosum
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(SG)/SC interface from the outermost SG cells (Menon
et al., 1992a). SG cells then rapidly form new LB (2–6 hours),
which propels further, accelerated LB secretion (Elias et al.,
1998). LB contain predominantly glucosylceramides and
phospholipids, which are metabolized by b-glucocere-
brosidase acidic sphingomyelinase and secretory phospho-
lipase A2 in the extracellular spaces into ceramides and
free fatty acids, respectively, forming the mature lamellar
membranes (Holleran et al., 1992; Mao-Qiang et al., 1996).
Thus, within a relatively short period of time, LB secretion,
followed by the extracellular processing of precursor
lipids derived from LB, restores lamellar membranes within
the SC interstices, thereby normalizing permeability barrier
function.
Although the factors that regulate this homeostatic repair
response are still incompletely understood, changes in the
concentrations of extracellular calcium, and to a lesser
extent, potassium, surrounding SG cells, play an important
role (Menon et al., 1992a). In normal epidermis, there is a
characteristic intraepidermal calcium gradient, with peak
concentrations of calcium surrounding the SG layer (Mauro
et al., 1998). Following permeability barrier disruption, the
concentrations of calcium surrounding the SG cells decline
abruptly, stimulating LB secretion (Menon et al., 1994). If the
calcium concentration surrounding the SG cells is artificially
maintained following barrier disruption, LB secretion does
not occur and the barrier is not repaired (Menon et al., 1994).
In addition to regulating LB secretion, the high calcium
concentrations in the outer epidermis also regulate the
differentiation of keratinocytes and the formation of the
cornified envelope (Yuspa et al., 1989; Elias et al., 2002a).
Specifically, high levels of calcium stimulate the expression
of proteins required for keratinocyte differentiation, including
key structural proteins of the cornified envelope, such as
loricrin, involucrin, and the enzyme, transglutaminase 1,
which catalyzes the crosslinking of these proteins into a rigid
structure (Elias et al., 2002a).
The SC contains three families of proteases (ie serine,
cysteine, and aspartate proteases), including the epidermal-
specific serine proteases (SP), kallikrein-5 (SC tryptic enzyme,
SCTE) (Brattsand and Egelrud, 1999), and kallikrein-7 (SC
chymotryptic enzyme) (Hansson et al., 1994), as well as at
least two cysteine proteases, including the SC thiol protease
(SCTP) (Bernard et al., 2003), and at least one aspartate
protease, cathepsin D (Horikoshi et al., 1998). Following
barrier disruption, SP activity increases in the SC (Denda
et al., 1997), and inhibition of SP, but not of other proteases,
accelerates normalization of permeability barrier function
(Denda et al., 1997). One explanation for the SP inhibitor
(SPI)-mediated acceleration could relate to the observation
that sustained SP activation degrades the extracellular lipid-
processing enzymes required for formation of the mature
lamellar membranes (Hachem et al., 2005). However, our
preliminary studies suggested instead that the initial accel-
eration of barrier recovery after SPI applications was linked to
increased LB secretion, rather than enhanced extracellular
processing, suggesting that SP activation in the SC impacts SG
secretory function.
SP, such as trypsin and thrombin, are activators of
G-protein-coupled receptors, the protease-activated receptors
(PARs) (Coughlin, 2000; Macfarlane et al., 2001). PARs are
characterized by a unique mechanism of activation, that is,
receptor cleavage by SPs generates a peptide, called a
‘‘tethered ligand’’, from the N-terminal domain of the
receptor. Thrombin and, to a lesser degree, trypsin primarily
activate PAR-1 (Rasmussen et al., 1991). In contrast, PAR-2 is
insensitive to thrombin, but is instead activated by mast cell
tryptase, trypsin, and a variety of other endogenous and
exogenous SP (Nystedt et al., 1995). A recent report,
describing high levels of PAR-2 in the outer epidermis
(Steinhoff et al., 1999), is consistent with a role for PAR-2 as
the primary sensor of barrier-initiated kallikrein-5 activity
(Seeliger et al., 2003; Iwakiri et al., 2004). But other reports
have shown instead either preferential expression of PAR-2 in
the basal layer and/or suprabasal expression that correlates
with skin-pigment phototype (Scott et al., 2001; Seiberg et al.,
2003), unrelated to permeability barrier homeostasis (Hou
et al., 1998). Hence, PAR-2 is most likely not the unique
pathway for SP signaling. Indeed, mice lacking the mem-
brane-anchored channel-activating SP 1 show impaired
permeability barrier and the examination of tight-junction
proteins reveals the absence of occludin (Leyvraz et al.,
2005). But, the proteases that activate channel-activating SP 1
are still unknown and channel-activating SP 1 are cleaved as
a consequence of SC kallikreins cascade (Brattsand et al.,
2005). In this paper, we address the PAR-2-dependent SP
signaling in the SC in regulating permeability barrier home-
ostasis and most specifically LB. Specifically, we show that
acute barrier disruption increases SP activity, and that
applications of SPI improve barrier recovery kinetics follow-
ing acute abrogation both in normal humans and in mice,
paralleled by decreased SP activity. Moreover, we demon-
strate here unequivocally that PAR-2 is expressed preferen-
tially in the suprabasal layers of both human and murine
epidermis, is unrelated to pigment type and most specifically
localizes to lipid raft (LR) domains under basal conditions.
To further address the role of PAR-2 signaling in mediating
the downstream effects of increased SP, we show that while
PAR-2 is activated following acute barrier abrogation and
PAR-2 agonist peptide impedes barrier homeostasis in an
SP-dependent fashion, permeability barrier recovery conver-
sely accelerates in PAR-2 knockout (ko) mice. Finally, we
show that both the SP/SPI-mediated modulations of barrier
homeostasis and the differences in barrier recovery in PAR-2
agonist peptide-treated versus ko mice can be attributed to
divergent regulation of epidermal LB secretion.
RESULTS
SPI accelerate permeability barrier recovery in normal humans
Prior studies have shown that acute permeability barrier
disruption increases epidermal SP activity, and that topical
SPI accelerate barrier recovery of murine skin after acute
disruption (Denda et al., 1997). Therefore, we first assessed
here whether topical SPI also improve barrier recovery
kinetics in normal human skin. Immediately after acute
barrier disruption by sequential tape stripping of four sites on
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both forearms of 10 young, normal adults (genders equally
represented), we applied the tryptic/chymotryptic inhibitor,
aprotinin, the plasminogen activator inhibitor, trans-4-(ami-
nomethyl) cyclohexane carboxylic acid (t-AMCHA), or the
vehicle to acutely disrupted skin sites. Both aprotinin and
t-AMCHA significantly accelerated the kinetics of barrier
recovery after acute disruption, computed as the area under
the recovery curves between 0 and 24 hours after disruption
(Figure 1). Thus, topical SPI accelerate permeability barrier
recovery in human skin.
SPI block SP upregulation and accelerate permeability barrier
recovery after acute barrier disruption of mouse skin
To further assess the role of SP/SPI balance in epidermal
permeability barrier homeostasis, changes in SP activity and
barrier recovery kinetics were evaluated in hairless mice
3 hours following tape-stripping, followed by immediate
application of different SPI (Table 1). SP activity, evaluated
by in situ zymography, increased after barrier disruption
(Figure 2a). SP activity remained elevated in E64 (cysteine
protease inhibitor, not shown)-, and EDTA (metalloproteinase
inhibitor)-treated, disrupted skin sites (Figure 2g), while
topical application of several chemically unrelated SPI
(pentamethylsulfonyl fluoride (PMSF), chymostatin, aprotinin,
t-AMCHA) blocked the expected increase in SP activity
(Figure 2c–f). All of these SPI also significantly accelerated
barrier recovery kinetics in comparison to either vehicle
alone or inhibitors of other proteases (E64 and EDTA)
(Table 1). These results show first, that SP activity increases
after barrier abrogation; second, that topical SPI specifically
block the increase in SP activity; and third, that topical SPI
also specifically accelerate barrier recovery in normal murine
skin.
SPI-induced improvement in barrier recovery can be ascribed
to enhanced LB secretion
Normal permeability barrier recovery is dependent upon both
the synthesis of epidermal lipids and the generation of
abundant LB, followed by rapid, polarized secretion of LB
contents at the SG–SC interface. There were no significant
differences in synthesis of either nonsaponifiable or saponifi-
able lipids in mice with disrupted barriers, treated with SPI
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Figure 1. Single application of either aprotinin or t-AMCHA, two SPI
improve barrier recovery by normal human volunteers. TEWL was measured
both under basal conditions and immediately (0 hour), 3, 24 hours following
acute barrier disruption by repeated D-Squame tape stripping (20–25
D-squames per site). Applications of either aprotinin or t-AMCHA
immediately after tape stripping significantly improved barrier recovery in
comparison to vehicle-treated and nontreated air-exposed skin sites. Results
shown are the mean of the areas under the curve (AUC)7SEM of the TEWL
measurements at 0, 3, and 24 hours.
Table 1. Serine protease inhibitors improve barrier
recovery after acute disruption
Treatment
Barrier recovery
(% change7SD)
Significance
(P-value)
Vehicle 46.974.7 —
PMSF (1 mM) 59.671.5 Po0.01
PMSF+AP1 (10 mM) 41.8712 NS
Aprotinin (10%) 62.974.6 Po0.05
t-AMCHA (20%) 61.072.0 Po0.01
STI (10%) 70.677.7 Po0.01
Chymostatin (1mM) 65.678.3 Po0.01
E64 (1 mM) 34.673.6 NS
EDTA (1 mM) 3174.6 NS
Acute barrier disruption by repeated cellophane tape stripping was
performed, followed by the application of SPI (soybean trypsin inhibitor
(STI), aprotonin, chymostatin, pentamethylsulfonyl fluoride (PMSF), and
trans-4-(aminomethyl) cyclohexane carboxylic acid (t-AMCHA)) or
protease inhibitors with no SP specificity (E64 and EDTA) in propylene
glycol:ethanol (PG:E 70:30), as well as PG:E alone. TEWL was measured
both immediately after and 3 h after acute barrier disruption. Results shown
represent the means7SD (n=4–6 in each group). NS, nonsignificant.
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Figure 2. Acute barrier disruption increases epidermal proteolytic activity,
as shown by in situ zymography. Acute barrier disruption by repeated
cellophane tape stripping was performed on hairless mice skin followed by
the topical application of various SPI (c, PMSF; d, soybean trypsin inhibitor;
e, t-AMCHA; f, chymostatin), non-serine type PI (g, EDTA) in propylene
glycol:ethanol (PG:E; 70:30 vol:vol) or (a) vehicle alone. (e, f) Application
of SPI inhibits the tape stripping-induced increase in SP activity, (a) while
non-SP-type inhibitors did not block the increase in SP that follows acute
barrier disruption. (b) Basal SP activity prior to barrier disrution. SC: stratum
corneum. Bar¼ 10mm.
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versus vehicle (see Supplementary Figure 1). Therefore, we
next assessed the morphological basis for accelerated barrier
recovery in disrupted skin sites treated with either SPI or
vehicle. Ultrastructural studies demonstrated normal (ie, no
differences in) extracellular lamellar membrane structures in
SPI versus vehicle-treated skin (not shown). Instead, we
observed an immediate (ie, within 15–30 minutes), substantial
increase in deposition of LB contents at the SG–SC interface
in SPI-treated skin sites (Figure 3a–d). Quantitative studies
also demonstrated a significant enhancement of LB secretion
in SPI-treated versus control samples (Figure 3e). Together,
these data show that the SPI-mediated acceleration of barrier
recovery is paralleled by an increase in LB secretion.
PAR-2 localizes to LR domains within the suprabasal cell layers
of both mouse and human epidermis
If the effects of SP/SPI on barrier function are mediated by
PAR-2, we hypothesized that this receptor should then
preferentially localize to the outer epidermis. Therefore, we
next localized PAR-2 protein by immunofluorescence stain-
ing in mouse and human epidermis. We first addressed the
specificity of the H99 rabbit anti-PAR-2 antibody (rodent and
human-specific) to PAR-2 protein by immunofluorescence of
frozen sections of PAR-2 ko versus wild-type (wt) mice
(Figure 4a and b, respectively). PAR-2 wt (BL6 background)
and sections from hairless mouse skin, but not ko epidermis,
demonstrate a suprabasal pattern of PAR-2 expression, largely
restricted to the outer nucleated cell layers (Figure 4b and c vs
a). The absence of PAR-2 immunostaining in ko mice
substantiates the specificity of antibody staining of the
receptor. Since most of the functional studies with SPI and
PAR-2 agonists were performed in hairless mice, we next
assessed PAR-2 localization in normal hairless mouse
epidermis, using the H99 antibody. PAR-2 protein again is
expressed preferentially in suprabasal, nucleated cell layers
(Figure 4c). These results show that PAR-2 preferentially
localizes to suprabasal epidermal layers in mouse epidermis.
Finally, to determine H99 antibody specificity for PAR-2, we
next assessed PAR-2 immunolocalization following applica-
tion of either the exogenous PAR-2 agonist (AP1:SLIGRL) or a
control (scrambled) peptide (CP1:ISSLRG) to human cultured
keratinocytes. PAR-2 activation by AP1 leads to progressive
internalization of PAR-2 over time, but no internalization of
receptor occurs in cells treated with the control peptide, as
visualized by immunohistochemical staining (Figure 5).
Knowing that G-coupled protein receptors localize to LR
plasmatic membrane domains, we next addressed the
specific subcellular expression of PAR-2 within cellular
compartments by Western immunoblotting on epidermal
fraction from either membrane, LR, and cytoplasmic domains
of murine epidermis (Simons and Ikonen, 1997). As shown in
Figure 6a, and under basal conditions, PAR-2 mainly
localizes to LR while absent in both cytoplasmic and
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Figure 3. SPI enhance LB secretion in mouse skin. (a–d) SPI-treated
(aprotinin, PMSF, t-AMCHA) skin sites show a massive increase in LB
secretion at the SG/SC junction in comparison to vehicle-treated skin.
Arrowheads show areas of LB protrusion at the SG/SC junction. (a–d) Osmium
tetroxide post-fixation. Bar¼ 0.25mm. (b) Quantitative electron microscopy
analysis for LB secretion shows a significant increase in secreted LB density of
SPI-treated (aprotinin, PMSF, t-AMCHA) versus control sites. The ratio
between paper weight of traced secretion area at the SG/SC junction and the
total length of the first SC cell layer was used to determine LB secretion
density. (e) Results shown represent the means7SEM (n¼ 30 randomly
selected, coded micrographs from three animals per treatment).
a
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c
PAR2 ko
PAR2 wt
Hairless mouse
Figure 4. PAR-2 is expressed in the suprabasal epidermal layers in murine
skin. PAR-2 immunostaining was performed using rabbit polyclonal
anti-PAR-2 (H99, Santa Cruz Biotechnology, California) antibody and
anti-rabbit Alexas Fluor secondary antibodies (Molecular Probes, Eugene).
H99 specificity was verified on (a) PAR-2 ko mice showing absence
of immunostaining in comparison to (b) wt littermates and in
(c) hairless mice epidermis. Bar¼10 mm.
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membrane domains. Since activated PAR-2 is known to be
endocytosed and degraded (Bohm et al., 1996; Dery et al.,
1999), we addressed whether SC tape stripping mobilizes
PAR-2 from the LR domain to the cytoplasm as a conse-
quence of activated PAR-2-dependent internalization. We
found that acute barrier abrogation by tape stripping
decreased PAR-2 protein within the LR domains 30 minutes
following tape stripping (Figure 6b). In parallel, while under
basal conditions PAR-2 is virtually absent within the
cytoplasmic domains (Figure 6a), increased immunostaining
appears as early as 30 minutes following tape stripping,
indicating receptor internalization (Figure 6c). Together,
these results demonstrate the functional consequences of
PAR-2 activation in vitro culture human keratinocytes and in
vivo murine epidermis, as well as prove antibody specificity
by unrelated, biological approaches (c.f., antibody staining
for PAR-2 in ko vs wt epidermis and AP1-induced inter-
nalization of PAR-2 in cultured keratinocytes). Together with
the predominantly suprabasal localization of PAR-2 in rodent
and human epidermis, these results support a central role for
PAR-2 in SP/SPI signaling of barrier homeostasis. The
localization of PAR-2 in human epidermis is controversial,
and, even when shown to be suprabasal, immunostaining has
been reported to be dependent upon pigment phototype
(Babiarz-Magee et al., 2004). Therefore, we next localized
PAR-2 in human epidermis in non-UV-exposed, Fitzpatrick
phototype II human epidermis, by both immunohistochem-
istry on frozen sections and Western immunoblotting, using
both the H99 and N-terminal-specific antibodies. As in
murine epidermis, PAR-2 distribution, detected by the H99
antibody, again preferentially localizes to suprabasal, cell
layers in human epidermis (Figure 7a). Moreover, Western
immunoblotting, using anti-PAR-2 N-terminal antibody,
performed on protein extracted from basal, suprabasal and
normal, full-thickness human epidermis, show equivalent
PAR-2 expression, restricted to the outer epidermis (Figure
7b). Together, these results demonstrate the preferential,
CP AP
a b
Figure 5. PAR-2 internalization following activation with agonist peptide
confirms that receptor is functional. Cultured human keratinocytes (CHK)
were incubated for 30 minutes with either (a) agonist peptide (AP2; 0.1 mM:
panel or (b) control peptide (CP2; 0.1 mM), after which immunohistochemical
staining was performed using the H99 antibody. (a) A decrease in cell
membrane staining following AP2-dependent PAR-2 activation is observed
over time as a consequence of receptor internalization, showing that receptor
expressed in differentiated keratinocytes is functional, as well as further
confirming antibody specificity for PAR-2 protein. (b) Arrows show
noninternalized, membrane staining in cells treated with control peptide.
Bar¼10 mm.
1
0 30 minutes 3 hours 8 hours 24 hours
2 3 4 5 6 7 8 9
51 kDa
51 kDa
51 kDa
Cytoplasm
LR
a
b
c
Figure 6. PAR-2 is internalized from LR domain to cytoplasm following
barrier abrogation. (a) Proteins from mouse epidermis were extracted by
protein fractioning extraction into three compartments: membranes (1–3),
LR (4–5), and cytoplasm. As observed, immunoblotting for PAR-2 using
N-terminal antibody (Novus Biological, Montlucon, France) shows positive
staining in the LR fraction. The amount of proteins loaded was as follows: 1, 4,
7¼ 5 mg; 2, 5, 8¼ 10mg; and 3, 6, 9¼ 15 mg. (b, c) Immunostaining for PAR-2
significantly decreases in the LR domains as early as 30 minutes (300)
following tape stripping-induced barrier abrogation in comparison to basal
control (0 hours). On the contarary PAR-2 immunostaining significantly
increases with the cytoplasm 300 following barrier abrogation and is
maintained at 3, 8, and 24 hours. (b and c) Equal amounts of proteins were
loaded on blot.
50 kDa
PAR-2
1 2 3
37 kDa
-Actin
SC
SG
SP
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a b
Figure 7. PAR-2 protein is present in suprabasal layers of human epidermis,
independent of skin phototype. (a) PAR-2 expression was performed on
frozen sections from human phototype II skin, showing again a suprabasal
membrane type distribution using H99 antibody. White arrows show PAR-2
membrane staining; SC: stratum corneum; SG: stratum granulosum; SP:
stratum spinosum; SB: stratum basale. (b) Protein extracts from upper basal
(B1), whole (B2), and upper human epidermis (B3) were loaded onto
SDS-PAGE gels. After transfer onto nitrocellulose membrane, immunoblotting
was performed using anti-PAR-2 N-terminal antibody (Novus Biological,
Montlucon, France) at 41C overnight. Blots show the strong presence of
PAR-2 protein isoforms in the upper epidermis, corresponding to the
previously described, 45–100 kDa sizes that correspond to glycosylated
forms of PAR-2. Equal amounts of proteins were loaded on each blot and
loading control was performed by immunoblotting with rabbit anti-b-actin
(Novus Biological, Montlucon, France).
2078 Journal of Investigative Dermatology (2006), Volume 126
J-P Hachem et al.
Epidermal Permeability Barrier Homeostasis
suprabasal localization of functional PAR-2 in the human and
mouse epidermis.
While PAR-2 activation delays barrier recovery, PAR-2 ko
conversely accelerates recovery
To determine whether the SP/SPI effects on barrier home-
ostasis are mediated by PAR-2, we next assessed the effects of
PAR-2 agonist stimulation versus ko on permeability barrier
homeostasis. In the first set of studies, the agonist peptide
(AP1, 10 mM), control peptide (CP1, 10 mM), PMSF alone, or
PMSF (1 mM)þAP1 were applied to tape-stripped sites on
hairless mice, and barrier recovery kinetics were compared at
various time points after acute disruption. AP1 significantly
delays barrier recovery in comparison to CP1, with the
greatest differences observed at 3 hours (Figure 8a). Since the
PMSF-induced improvement in barrier recovery is abolished
when PMSF is coapplied with AP1, SPI block SP prior to
ligand binding, rather than by competing at the level of the
receptor. We next compared permeability barrier home-
ostasis in PAR-2 ko versus wt mice. PAR-2 ko mice display a
significant acceleration in barrier recovery kinetics in
comparison to wt mice 3 hours following acute barrier
abrogation by tape stripping (Figure 8b). Together, these
results show that PAR-2 activation delays barrier recovery in
an SP-dependent fashion, and second, that PAR-2 signals
certain downstream, negative effects of SP on permeability
barrier homeostasis.
PAR-2 effects on barrier homeostasis are attributable to altered
LB production/secretion
We next assessed whether the SPI/PAR-2-mediated effects on
barrier homeostasis were attributable to stimulation of
acceleration of LB secretion, as with SPI treatment (see
above). To examine the structural basis for the PAR-2-
stimulated changes in barrier homeostasis, we assessed the
LB secretory system in AP1- versus CP1- and vehicle-treated
murine skin by electron microscopy. The polarity of LB
secretion appears to diverge from the apex (SG–SC interface)
to the periphery of outer SG cells by 3 hours after AP1
applications to abrogated skin sites (Figure 9). In addition,
sequestration of incompletely secreted (entombed) LB is
evident in API-treated corneocytes, a further indication of
impaired LB secretion (Figure 9). In contrast, PAR-2 ko mice
show enhanced LB secretion in comparison to wt mice both
prior to and 3 hours after barrier abrogation (Figure 10). In
addition, increased secretion is further confirmed by lipase
cytochemistry (Figure 11), and by enhancing SC membrane
staining in PAR-2 ko mice in comparison to wt littermates
(Figure 12a and b). Furthermore, PAR-2 ko epidermis shows
increased expression of an independent marker of caveolin/
LB secretion (Figure 12e and f). Finally, lipid insertion into
the plasma membrane, indicative of formation of LR in
suprabasal epidermis, is demonstrated by cholera toxin-B
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Figure 8. PAR-2 receptor regulates negative effects of SP on permeability
barrier homeostasis. (a) Immediately after cellophane tape stripping, animals
were treated with a single application of the PAR-2 agonist peptide (AP1:
SLIGRL), control peptide (CP1: ISSLRG), PMSF alone (1 mM), AP1þ PMSF or
vehicle (propylene:glycol ethanol; 70:30). TEWL was measured immediately
after and 3 hours after acute barrier disruption and statistical analysis was
assessed in comparison with vehicle control. A significant delay in barrier
recovery is apparent in agonist peptide versus CP application sites. The
negative effects of agonist peptide could be prevented by coapplications of
PMSF. (b) Tape stripping was performed on PAR-2 ko mice and wt littermates.
In ko mice barrier, recovery is accelerated 3 hours following acute disruption.
Results shown represent the means7SEM (n¼ 4–6 mice in each group).
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Figure 9. PAR-2 agonist peptide-induced delay in barrier recovery can be
ascribed to altered LB secretion. (a, c) PAR-2 agonist peptide (AP1)-treated
skin. (b) Control peptide (CP1)-treated skin. (a, c) Entombed LB (arrow heads)
as high as the (c) third SC layer (SC3). Control peptide shows normal electron
microscopy features, as seen in vehicle-treated and untreated epidermis (not
shown). SG: stratum granulosum; dots indicate the SG/SC interface, arrows
showing areas of LB secretion. (a–c) Osmium tetroxide post-fixation.
Bar¼0.25 mm.
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immunolabeling (Figure 12c and d). Together, these results
suggest that SP-PAR-2 signaling affects barrier homeostasis by
regulating the extent of LB secretion, and that secretion
results in the formation of both caveolae and LR in the outer
nucleated layers of the epidermis.
DISCUSSION
By delivering key lipid precursors and colocalized lipid
hydrolases, the LB secretory system is critical for main-
tenance of permeability barrier homeostasis (Menon et al.,
1992a). Moreover, LB secretion responds to perturbations in
barrier function, not only through the immediate delivery of
preformed LB contents to the SG–SC interface (Menon et al.,
1992a) but also by accelerated formation and secretion of
nascent organelles (Menon et al., 1992a). The sudden decline
in extracellular calcium ions, which accompanies such acute
perturbations (Mauro et al., 1998), is a well-studied signal of
the amplified LB secretory response to acute barrier
perturbations (Denda et al., 2003). Yet, the signals that
regulate LB secretion under basal (maintenance) conditions
are unknown, and it is likely that other factors, in addition to
calcium, could further regulate the LB secretory response to
barrier insults.
SC SC
C
KO KO-TS
SC
WT
SG
SG SG
a b c
Figure 10. Absence of PAR-2 correlates with enhanced LB secretion.
Enhanced LB secretion is observed in PAR-2 ko mice both (b) before and
(c) after tape stripping-induced barrier disruption. Open arrows show the
presence of LB secretion deep in the epidermis, even in the (b) basal state, and
a further upregulation at the (c) SG/SC junction 3 hours following tape
stripping (black arrow). Arrowheads show cytosolic LB with normal
polarization towards the apical membrane in preparation for secretion in
(b, c) ko mice compared to (a) wt littermates. (a–c) Osmium tetroxide
post-fixation. Bar¼ 0.05 mm.
SC
SC
SC
SC
SC
SC
SG
SG
SG
SG
SG
SG
WT
PAR-2 ko
PAR-2 ko
PAR-2 koa
b
c
d
e
f
WT
WT
Figure 12. Absence of PAR-2 correlates with enhanced SC membrane
staining, and increased LR/caveolae formation. (a, b) SC membrane domains
were stained with FMs lipophilic styryl dyes that insert into the outer leaflet
of the surface membrane, showing enhanced fixation of the fluorescent dye in
(a) PAR-2 ko versus (b) wt littermates. (c–f) LR formation assessed by cholera
toxin-B assay (c vs d) and caveolin-1 expression (e vs f) is significantly
increased in (c, e) PAR-2 ko animals compared to (d, f) wt littermates. Dots
indicate the SG/SC interface. Bar¼ 10 mm.
wt ko
0.5 m
0.5 m
a b
Figure 11. Increased LB secretion in PAR-2 ko mice correlates with
increased neutral lipase activity. Cytochemical staining for neutral lipase was
performed on aldehyde-fixed sections from skin biopsies from (b) PAR-2 ko
versus (a) wt littermates. An increase in neutral lipase cytochemical staining
(arrows) is observed in PAR-2 ko mice, which correlates strongly with
enhanced LB secretion observed on conventional electron microscopy
(ie Figure 10). Arrows indicate areas of LB secretion, while arrowheads
show cytosolic LB. Bar¼ 0.05mm.
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The present study points to SP activation as a second signal
that regulates the LB secretory response. We confirmed here
first, prior observations that SP activity increases after acute
perturbations of the permeability barrier. We showed here
further that inhibition of SP activation with topical SPI
accelerates barrier recovery not only in rodents (see also
Denda et al., 1997), but also in humans. Whereas increases
in SP activity induced by another approach, that is, increases
in pH, alter barrier function by increasing the degradation of
key lipid-processing enzymes (Hachem et al., 2005), we
found unexpectedly that neither lipid synthesis nor lipid-
processing were altered by SPI; instead, SPI treatment
accelerated LB secretion. These observations suggest that SP
suppress the LB secretory responses to acute barrier
perturbations.
Whereas these observations demonstrate a new signaling
role for SP in regulating permeability barrier homeostasis, we
further assessed the mechanism by which increased SP
activity downregulates LB secretion. SP-mediated activation
of PAR is well known to regulate both the coagulation
cascade and inflammation (Coughlin and Camerer, 2003;
Steinberg, 2005), and the tryptic-like subfamily of SP
specifically bind to the PAR-2 receptor. Appropriate for its
putative role in regulating LB secretion, we showed that PAR-
2 is preferentially expressed in the outer nucleated layers of
the epidermis (see also Steinhoff et al., 1999), the same level
where LB are formed and secreted (Elias et al., 1998; Rassner
et al., 1999). We show further that LB secretion accelerates in
PAR-2 ko animals in parallel with acceleration of barrier
recovery. Thus, absence of PAR-2 mimics the effects of
topical SPI on LB secretion and barrier recovery kinetics.
Conversely, applications of a PAR-2 agonist peptide to the
surface of acutely disrupted skin sites both suppress LB
secretion and mimic the SP-associated delay in barrier
recovery. This accelerated LB secretion in the absence of
PAR-2 were demonstrated not only ultrastructurally but also
by immunohistochemical evidence of increased caveolin-1
insertion into the plasma membrane of SG cells, coupled with
increased formation of LR at the same sites. Thus, increased
SP activity, generated in the outer epidermis, appears to
negatively regulate LB secretion by activating PAR-2. This
mechanism diverges from Ca2þ , where steep reductions in
Ca2þ stimulate LB secretion.
The teleologic basis for such a ‘‘negative’’ signal is,
however, not yet known. The SC of vertebrate epidermis
comprises a unique, two-compartment system of anucleated,
protein-enriched corneocyte ‘‘bricks’’ embedded in a lipid-
enriched, extracellular matrix ‘‘mortar’’ (Elias, 1983). Both
compartments are required to form an effective permeability
barrier. Whereas the hydrophobic lipids of the SC interstices
block water movement (Elias et al., 1988; Madison, 2003),
the corneocyte ‘‘bricks’’ provide a scaffold necessary for the
organization of the extracellular lipids into lamellar mem-
branes (Elias et al., 2002b). Therefore, one explanation for SP-
mediated, downregulation of LB secretion after acute
perturbations could be that this process is coordinated with
corneocyte formation (¼physiologic apoptosis) to form the
two-compartment structure required for barrier function.
With cornification, cells that are transitioning into corneo-
cytes lose their secretory competence (Roop, 1995). Thus, by
providing a prompt response to external insults, SP activation
of PAR-2 could regulate a rapid, coordinated, homeostatic
response that facilitates the transition of cells in the outer SG
into the lower SC (Ahn et al., 1999). Accordingly, in
preliminary studies, we have shown that acute barrier
perturbations induce apoptosis, accompanied by transition
of outermost SG cells into corneocytes, a sequence that is
enhanced by PAR-2 agonists and blocked by topical SPI
(unpublished observation). Further studies are underway to
delineate the downstream signaling mechanisms that co-
ordinate SP-PAR-2 regulation of LB secretion and physiologic
apoptosis. Together, these studies support the view that SP-
mediated signaling stimulates responses by both the differ-
entiating keratinocyte and the LB secretory machinery, which
are appropriate for the formation of both components of the
SC and permeability barrier restitution (Figure 13).
SP participate with other signaling molecules in the
orchestration of permeability barrier homeostasis (Figure
13). For example, while a sharp reduction in extracellular
calcium following barrier disruption stimulates LB secretion,
high calcium levels under basal conditions restrict exocytosis,
but upregulate corneocyte protein synthesis (Bikle et al.,
2001). Recent studies have shown that activators of class II
nuclear hormone receptors display diverse effects on LB
secretion and corneocyte formation. While retinoids inhibit
cornification, but enhance LB production/secretion, activa-
tors of the liposensor subfamily, for example, PPARa, b/d, g,
and LXR, stimulate both differentiation (Komuves et al., 2000;
Mao-Qiang et al., 2004; Schmuth et al., 2004) and LB
production/secretion (Komuves et al., 2000; Mao-Qiang
et al., 2004; Schmuth et al., 2004). In contrast, other known
signals of permeability homeostasis, such as cytokines and
growth factors, do not appear to regulate LB secretion, but
instead, they stimulate epidermal mitogenesis and/or lipid
synthesis in response to barrier perturbations (Jensen et al.,
1999; Steude et al., 2002; Hatano et al., 2005, Figure 13).
The downstream pathway, which follows SP binding to
PAR-2, leading to LB secretion, is not known. All PARs are
‘‘single-use’’ receptors, which indicates that proteolytic
cleavage exposes the initially tethered ligand, which is
followed by internalization (Stalheim et al., 2005) and
Barrier disruption
Barrier recovery
Corneocytes
PAR1r
PAR2r
SP
LB secretionLB production
& secretion
DNA synthesis
Lipid synthesis
Cytokines,
Ca2+growth factors
pH
Figure 13. Signaling events linking barrier disruption to recovery.
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lysosomal degradation of the ligand–receptor complex (Jacob
et al., 2005). Certain structural features that are unique to the
outermost SG layer facilitate LB secretion. These include
(Madison et al., 1988; Elias et al., 1998): (1) a widely
disbursed trans-Golgi network from which LB are formed by
budding and membrane ‘‘consumption’’; (2) invaginations of
the apical plasma membrane of outermost SG cells that
extend deep into the cytosol; and (3) simultaneous side-to-
side and end-to-end, organelle fusion (ie, compound
exocytosis). Whether SP-PAR-2 signaling regulates one or
more of these cellular processes remains to be explored.
Finally, findings in this study have potential clinical and
therapeutic implications. Increased SP activity occurs in a
variety of clinical settings, ranging from genetic disorders,
such as Netherton syndrome, where absence of a specific SPI,
the lymphoepithelial, Kazal-type inhibitor, leads to poten-
tially devastating consequences for SC structure and function
(Bitoun et al., 2003), to the irritation that accompanies the use
of alkaline soaps (Seidenari and Giusti, 1995). Furthermore,
most, if not all, inflammatory dermatoses are characterized
by an increase in epidermal protease activity (Wiedow et al.,
1992; Yawalkar et al., 2001; Kastelan et al., 2004; Komatsu
et al., 2005), along with a coexistent permeability barrier
abnormality (Ghadially et al., 1996; Macheleidt et al., 2002),
which may drive disease phenotype (Ghadially et al., 1996;
Chamlin et al., 2001, 2002). Barrier dysfunction in these
disorders is further associated with an increase in surface pH
(Eberlein-Konig et al., 2000; Rippke et al., 2004), which,
along with increased water and calcium content of perturbed
SC (Fairley, 1991; Karvonen et al., 2000), create conditions
that would all favor SP activation (Figure 13). Thus, SPI/PAR-2
antagonism could provide a set of novel pharmacological
interventions, which could be employed to treat inherited
and acquired inflammatory dermatoses by regulating LB
secretion, thereby normalizing barrier homeostasis.
MATERIALS AND METHODS
Materials
Male hairless mice (Skh1/hour), 6–8-week old, were purchased form
Charles River Laboratories (Wilmington, MA) and fed Purina mouse
diet and water ad libitum. PAR-2 ko (Lindner et al., 2000) and wt
littermates were kindly provided by Dr Shaun Coughlin from the
Cardiovascular Research Institute, University of California, San
Francisco. Propylene glycol, ethanol, and HCl were from Fisher
Scientific (Fairlane, NJ), while soybean trypsin inhibitor, aprotinin,
PMSF, t-AMCHA, E-64, EDTA, and dithiothreitol were from Sigma
Chemicals (St Louis, MO). Dispase (5,000 U/100 ml) in Hank’s
balanced salt solution was purchased from BD Biosciences (Brussels,
Belgium). PAR-2 agonist peptides (AP1: SLIGRL and AP2: SLIGKV;
human specific) and control (scrambled) peptides (CP1: ISSLRG and
CP2: VKGILS) were purchased from Eurogenetec (Lie`ge, Belgium).
Rabbit anti-human polyclonal (H99) was purchased from Santa Cruz
Biotechnology (Santa Cruz, CA), while rabbit polyclonal, anti-
human PAR-2 N-terminal domain antibody was from Novus
Biologicals (Interchim, FR). Goat anti-rabbit, Alexas-labeled sec-
ondary antibodies and EnzCheks Protease Assay Kit (green
fluorescence) were from Invitrogen (Merelbeke, BE). Horseradish
peroxidase-conjugated, anti-rabbit IgG was purchased from Vector
Labs (Burlingame, CA). [14C]acetate (56 mCi/mmol) was purchased
from American Radiolabeled Chemicals, Inc. (St Louis. MO).
All procedures were performed while mice were anesthetized
with chloral hydrate (Morton Grove Pharmaceuticals, Morton Grove,
IL), under a protocol approved by both the VA Animal Care and the
Vrije Universiteit Brussel Ethical Committees.
Assessment of permeability barrier homeostasis
Studies in human volunteers. A total of 16 healthy human
volunteers (4 males and 12 females, age(mean7SD)¼ 32.0779.02)
were included after signing an informed consent with the approval of
the Ethical Committee of the Academic Hospital (AZ-VUB, Brussels).
This study was conducted according to the Declaration of Helsinki
Principles. Transepidermal water loss (TEWL) was measured both
under basal conditions, as well as 3 and 24 hours following acute
barrier disruption by repeated D-Squame tape stripping (20–25
D-squames per site) and subsequent to 3 and 24 hours after the
application of aprotinin 10%, t-AMCHA (5 mM), or propylene
glycol:ethanol vehicle. Air exposed sites were used as untreated
controls.
Barrier homeostasis in animal models. Immediately after acute
barrier disruption by sequential cellophane tape stripping (TEWL
rates X4 g/m2/hour; normal p0.2 g/m2/hour), male hairless mice
(6–8 weeks) were treated with a single topical application of the
following SPI and other protease inhibitors: aprotinin (10%),
chymostatin (1mM), t-AMCHA (5 mM), PMSF (1 mM), soybean trypsin
inhibitor (5%), E64 (1 mM), and EDTA (10 mM) in propylene
glycol:ethanol (7:3 vol/vol) or vehicle alone. Similarly, either a
PAR-2 agonist peptide (AP1, 10 mM)7PMSF or the control peptide
(CP1, 10mM) were applied to the flanks of hairless mice after
cellophane tape stripping. Barrier recovery also was compared in
6-week-old PAR-2 ko mice versus wt littermates after tape stripping,
as above. Permeability barrier function was assessed as TEWL with
an electrolytic water analyzer (MEECOs; Warrington, PA) (Orsmark
et al., 1980), before and immediately after, as well as 3 hours after
acute barrier disruption.
Assessment of SP activity by in situ zymography
Hairless mouse flanks were excised from treated animals and full-
thickness skin samples were then snap-frozen and stored at 201C.
Frozen sections (8 mm) were rinsed with a washing solution (1%
Tween 20 in deionized water) and incubated at 371C for 2 hours
with 250ml of BODIPY-Fl-casein (1mg/ml) in deionized water (2ml/
ml). Sections were then rinsed with the 1% Tween 20 washing
solution, coverslipped, and visualized immediately under a confocal
microscope (Leica TCS SP, Heidelberg, Germany) at an excitation
wavelength of 485 nm and an emission wavelength of 530 nm.
Immunohistochemistry
Skin sections. Mouse skin was excised from hairless mice, PAR-2
ko and littermate wt, while human skin samples (non-UV-exposed,
Fitzpatrick Phototype II) were obtained from surgical margins.
Frozen and paraffin-embedded tissue sections were incubated for
30 minutes in blocking buffer (1% BSA, 0.1% cold-water fish gelatin
in phosphate-buffered saline (PBS)), and then incubated for either
2 hours at room temperature with a 1:250 dilution of a rabbit
polyclonal antibody against PAR-2 diluted in blocking buffer. For
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caveolin-1 immunostaining, rabbit anti-caveolin-1 (Biosciences
Pharmingen, Erembodegem-Aalst, Belgium) was used. Tissue sec-
tions were then washed with PBS, and incubated for 1 hour at room
temperature with goat anti-rabbit antibody, diluted in blocking
buffer. Tissue sections then were washed with PBS, and visualized
under a confocal microscope (Leica TCS SP, Heidelberg, Germany)
at an excitation wavelength of 488 nm and an emission wavelength
of 518 nm.
Culture human keratinocytes. Second-passage culture human
keratinocytes were plated on coverslips placed in 100-mm plastic
dishes in serum-free keratinocyte growth medium (Cascade Bio-
logics, Portland, OR), containing 0.07 mM Ca2þ , and grown to 80%
confluence. The cells were then treated with either the AP2 (0.1 mM)
or CP2 (0.1 mM) peptide in the same medium. After 5–60 minutes,
coverslips were removed, fixed in 4% formaldehyde, and immuno-
stained with PAR-2 H99 antibody, as above.
Protein isolation from epidermis
Whole epidermis. After skin excision and removal of subcuta-
neous fat with scalpel blades, samples were floated dermis-side
down onto a Dispase solution 2.5 (caseinolytic units in PBS) at 41C
overnight. Subsequently, epidermal sheets were peeled off with
tweezers. Epidermal proteins were extracted by sonication (15 sec-
onds,  3) in extraction buffer (Tris base 62 mM, 2% sodium
dodeocyl sulfate containing a protease inhibitor cocktail).
Outer and lower human epidermal tissue fractions. After skin
excision and removal of subcutaneous fat with scalpel blades,
samples were floated dermis-side-downward on a 10 mM dithio-
threitol solution in PBS for 1.5 hours at 371C. Outer epidermal
sheets, comprising SC and SG plus stratum spinosum were removed
with tweezers, followed by removal of the residual stratum basale
from the dermis by gentle scraping with a scalpel blade (Holleran
et al., 1992).
LR, membrane, and cytoplasmic fractions. After skin excision
and removal of subcutaneous fat with scalpel blades, samples were
floated on 10 mM dithiothreitol solution in PBS for 1.5 hours at 371C.
Sub-cellular fractions were isolated using ReadyPrep Protein
Extraction Kits (Signal, Membrane and Cytoplasm; Biorad, Nazareth
Eke, Belgium) according to the manufacturers’ protocol.
Western immunoblotting
After protein isolation (see above), the protein content of whole,
basal, and suprabasal epidermal extracts was determined. Equal
amounts of protein from each experimental group were loaded onto
12% SDS-polyacrylamide gels. After electrophoresis in slab gels,
proteins were transferred onto nitrocellulose membranes and
immunoblotted to detect PAR-2 using the Western Lightening
chemiluminescence kit (Perkin-Elmer Life Sciences, Boston, MA).
Epidermal lipid synthesis
In all, 30 of 5 ml t-AMACHA or 10% soybean trypsin inhibitor was
applied to 2 3.5 cm tape-stripped area immediately following
barrier disruption. The vehicle-treated group served as control. Skin
samples were taken 2 hours after barrier disruption. Full skin samples
were incubated for 2 hours at 371C in 2 ml of 10 mM EDTA in PBS-
calcium an magnesium-free, containing 40 mCi [14C]acetate, as
described previously (Mao-Qiang et al., 1993). After stopping the
reaction by placing on ice, the epidermis was separated from the
dermis. The incorporation rates of [14C]acetate into free fatty acids
and cholesterol in epidermis were determined following saponifica-
tion, extraction, and thin layer chromatography, as described
previously (Mao-Qiang et al., 1993). The incorporation rate was
expressed as nM/g wet epidermal weight/hour.
Light and electron microscopy
Skin biopsy samples from all treatment groups (nX3 mice from each
group) were processed for light and electron microscopy. Briefly,
samples were minced to o0.5 mm3, fixed in modified Karnovsky’s
fixative overnight, and post-fixed in either 0.2% ruthenium tetroxide
or 1% aqueous osmium tetroxide, containing 1.5% potassium
ferrocyanide. After fixation, all samples were dehydrated in a graded
ethanol series, and embedded in an Epon-epoxy mixture. Ultrathin
sections were examined, with or without further contrasting with
lead citrate, in a Zeiss 10A electron microscope (Carl Zeiss,
Thornwood, NJ), operated at 60 kV.
Assessment of LB secretion
Quantitation of LB secretion. In order to quantify LB secretion in
electron micrographs, at least 10 pictures were taken randomly from
each sample at 16,000 magnification by an unbiased observer, and
the area filled by secreted LB contents within the SG–SC interface
was then traced, cut out, and weighed. LB density secretion was
defined as the ratio of secreted contents (as total weight) over the
length (in mm) of the bottom surface of the first SC cell layer,
determined with a planimeter.
Lipase cytochemistry. As ultrastructural cytochemical markers for
LB, we utilized neutral lipase known to be concentrated in this
organelle (Grayson et al., 1985). To visualize neutral lipase activity,
we used a method previously described by Rassner et al. (1999).
Samples were incubated in a medium containing 5% Tween 85
(1 ml) in 0.2 M N-hydroxyethylpiperazine-N0-2-ethanesulfonic acid
buffer (2.5 ml), 2.5% sodium taurocholate (2 ml), and 10% calcium
chloride (1 ml) in 25 ml distilled water (pH 7.4). Microwave
incubations were carried out according to the protocol described
below. After incubations, the samples were transferred for 3 minutes
into 2% EDTA in 0.1 M cacodylate buffer, rinsed three times in
distilled water, followed by incubation in 0.1% aqueous lead nitrate
for 10 minutes at room temperature.
Membrane staining. FMs lipophilic styryl dyes (Invitrogen,
Merelbeke, BE) are virtually non-fluorescent in aqueous media,
and get inserted into the outer leaflet of the surface membrane,
where they become intensely fluorescent. This method of membrane
labeling has been used to assess membrane staining in the SC of
PAR-2 ko. Frozen sections (8mm) were rinsed with PBS and
incubated with 5 mg/ml FMs 4–64 F for 1 minute. Sections were
then rinsed in PBS, fixed with 95% chilled ethanol for 5 minutes,
coverslipped, and visualized under a confocal microscope (Leica
TCS SP, Heidelberg, Germany) at an excitation wavelength of
565 nm and an emission wavelength of 744 nm.
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Assessment of LR/caveolae formation in PAR-2 KO animals
LR formation was analyzed in PAR-2 ko versus wt epidermis using
the Vybrant Lipid Raft Labeling Kit (Invitrogen, Merelbeke, BE).
Frozen sections (8mm) were rinsed with PBS and incubated at 371C
for 10 minutes with 100ml of 1mg/ml of cholera toxin-B subunit.
Sections were then rinsed with PBS and further incubated with 1/100
anti-cholera toxin B rabbit serum for 30 minutes, washed, cover-
slipped, and visualized immediately under a confocal microscope
(Leica TCS SP, Heidelberg, Germany) at an excitation wavelength of
485 nm and an emission wavelength of 530 nm.
Statistical analyses
Statistical analyses were performed using Prism 2 software (Graph-
Pad Software, San Diego, CA). Paired experimental groups were
compared with the Student t-test. Nonparametric Mann–Whitney
statistical analyses were performed to compare differences in
percent ratios between the various treatment groups.
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synthesis.
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